Testing HCP1803-4 for People With Essential Hypertension
Tests how well and how safely HCP1803-4 works in adults with high blood pressure.
Key facts
- Who runs it
- Hanmi Pharmaceutical Company Limited
- Where
- Goyang-si, South KoreaSee the site
- Trial code
- Registry title
- A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 256 people, planned
- Started
- 6 Jul 2026
- Expected to end
- 30 Nov 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- HCP1803-3
- HCP1803-4
- RLD2001-1
- RLD2001-2
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential hypertension (high blood pressure with no specific cause found). It tests the safety and effect of the study drug HCP1803-4.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Essential hypertension. At Visit 2, systolic blood pressure of 140 mmHg or more but below 180 mmHg, and diastolic blood pressure of 60 mmHg or more but below 110 mmHg.
- Earlier treatment
- People who took blood pressure medicine in the month before Visit 1 need systolic blood pressure below 180 mmHg and diastolic blood pressure below 110 mmHg at Visit 1. People who did not take it need systolic 140 mmHg or more but below 180 mmHg and diastolic 60 mmHg or more but below 110 mmHg. People who took more than three blood pressure medicine components in the 3 months before Visit 1 cannot join.
Main reasons for not taking part
- Blood pressure differs between the two arms by more than 20 mmHg (systolic) or 10 mmHg (diastolic) at Visit 1
- Secondary hypertension, or suspected secondary hypertension
- Severe heart disease or severe neurovascular disease
- Uncontrolled diabetes or type I diabetes
- Pregnant, breastfeeding, or planning pregnancy
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions; mean sitSBP < 180 mmHg and mean sitDBP < 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1; 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
- Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg at Visit 2
Who cannot take part
- Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
- Orthostatic hypotension with symptoms within 3 months prior to visit 1
- Severe heart disease or severe neurovascular disease
- Moderate or malignant retinopathy
- Uncontrolled diabetes mellitus or type I diabetes mellitus
- Severe renal diseases
- History of malignancy tumor
- History of autoimmune disease
- History of alcohol or drug abuse
- Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
- Secondary hypertensive patient or suspected to be
- Clinically significant hematological finding
- Active gout or hyperuricemia
- Severe or active hepatopathy
- Hypokalemia or Hyperkalemia
- Hyponatremia or Hypernatremia
- Hypercalcemia
- Positive to pregnancy test, nursing mother, intention on pregnancy
- Considered by investigator as not appropriate to participate in the clinical study with other reason
Where in South Korea
- Donggguk University Ilsan HospitalGoyang-si, South KoreaContact: Moo-Yong Rhee, M.D., Ph.D.Not yet recruiting
About the trial
What the trial wants to find out
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
The 2 groups in the trial
- HCP1803-4Treatment being tested
Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.
Treatment: HCP1803-3 and HCP1803-4
- RLD2001-2Existing treatment, for comparison
Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.
Treatment: RLD2001-1 and RLD2001-2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Plain-language title
- Testing HCP1803-4 for People With Essential HypertensionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 June 2026